ProGem1: Phase I first-in-human study of the novel nucleotide NUC-1031 in adult patients with advanced solid tumors.

被引：0
|
作者：
Ghazaly, Essam Ahmed
Joel, Simon
Gribben, John G.
Mohammad, Tariq
Emiloju, Oluwadunni
Stavraka, Chara
Hopkins, Tom
Gabra, Hani
Wasan, Harpreet
Habib, Nagy A.
Leonard, Robert C. F.
McGuigan, Christopher
Slusarczyk, Magdalena
Blagden, Sarah Patricia
机构：
[1] Queen Mary Univ London, Barts Canc Inst, London, England
[2] Univ London Imperial Coll Sci Technol & Med, NIHR Wellcome Trust Imperial Clin Res Facil, London, England
[3] Univ London Imperial Coll Sci Technol & Med, Dept Oncol, London, England
[4] Cardiff Univ, Sch Pharm & Pharmaceut Sci, Cardiff CF10 3AX, S Glam, Wales
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2576
引用
收藏
页数：1
相关论文
共 50 条
  • [41] First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors
    Bauer, Todd
    Cho, Byong Chul
    Heist, Rebecca
    Bazhenova, Lyudmila
    Werner, Theresa
    Goel, Sanjay
    Kim, Dong-Wan
    Adkins, Douglas
    Carvajal, Richard D.
    Alva, Ajjai
    Eaton, Keith
    Wang, Judy
    Liu, Yong
    Yan, Xiaohong
    Christensen, Jamie
    Neuteboom, Saskia
    Chao, Richard
    Pant, Shubham
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (05) : 990 - 1000
  • [42] First-in-human phase I study of SY-5609, an oral, potent, and selective noncovalent CDK7 inhibitor, in adult patients with select advanced solid tumors.
    Papadopoulos, Kyriakos P.
    Sharma, Manish
    Hamilton, Erika Paige
    Richardson, Debra L.
    Hodgson, Graeme
    Zhou, Li
    Volkert, Angela
    Jolin, Hina A.
    Madigan, Catherine
    Kelly, Michael
    Roth, David A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [43] First-in-human, first-in-class phase 1 study of a novel oral multi-AGC kinase inhibitor AT13148 in patients (pis) with advanced solid tumors.
    Kumar, Rajiv
    Mateo, Joaquin
    Smith, Alan D.
    Khan, Khurum Hayat
    Ruddle, Ruth
    Swales, Karen E.
    Decordova, Shaun
    Backholer, Zoe
    Jones, Paul
    Tran, Christine
    Seeramraddi, Satyanarayana
    McLeod, Robert
    Yap, Timothy Anthony
    Raynaud, Florence I.
    Garrett, Michelle D.
    Banerji, Udai
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [44] A first-in-human phase I dose-escalation study of MK-1496, first-in-class orally available novel PLK1 inhibitor, in patients with advanced solid tumors.
    Doi, T.
    Murakami, H.
    Wan, K.
    Miki, M.
    Kotani, H.
    Sakamoto, N.
    Yamamoto, N.
    Ohtsu, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [45] First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors
    Todd Bauer
    Byong Chul Cho
    Rebecca Heist
    Lyudmila Bazhenova
    Theresa Werner
    Sanjay Goel
    Dong-Wan Kim
    Douglas Adkins
    Richard D. Carvajal
    Ajjai Alva
    Keith Eaton
    Judy Wang
    Yong Liu
    Xiaohong Yan
    Jamie Christensen
    Saskia Neuteboom
    Richard Chao
    Shubham Pant
    Investigational New Drugs, 2022, 40 : 990 - 1000
  • [46] First-in-human phase 1 study of E7090, a novel selective inhibitor of FGFRs, in patients with advanced solid tumors
    Koyama, Takafumi
    Shimizu, Toshio
    Iwasa, Satoru
    Fujiwara, Yutaka
    Kondo, Shunsuke
    Kitano, Shigehisa
    Yonemori, Kan
    Shimomura, Akihiko
    Iizumi, Sakura
    Sasaki, Tatsuya
    Furuse, Junji
    Yamamoto, Noboru
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [47] First-in-human dose escalation, safety, and PK study of a novel EFNA4-ADC in patients with advanced solid tumors.
    Hong, David S.
    Garrido-Laguna, Ignacio
    Krop, Ian E.
    Subbiah, Vivek
    Werner, Theresa Louise
    Cotter, Christine M.
    Hamilton, Erika Paige
    Velastegui, Karen
    Xuan, Dawei
    Bugarini, Roberto
    Gollerkeri, Ashwin
    Burris, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [48] First-in-human, phase I study of AK109, an anti-VEGFR2 antibody, in patients (pts) with advanced or metastatic solid tumors.
    Xu, Nong
    Zheng, Yulong
    Zhong, Haijun
    Zhao, Fuyou
    Zhou, Huan
    Mao, Chenyu
    Lv, Wangxia
    Yuan, Meiqin
    Qian, Jiong
    Jiang, Haiping
    Wang, Zishu
    Xiao, Cheng
    Liu, Ting
    Liu, Wei
    Li, Baiyong
    Xia, Yu
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [49] First-in-human phase I and pharmacological study of TAS-119, a selective Aurora A (AurA) kinase inhibitor, in patients (pts) with advanced solid tumors.
    Robbrecht, Debbie
    Eskens, Ferry
    Calvo, Emiliano
    He, Xiaomin
    Hirai, Hiroshi
    Soni, Nital
    Cook, Natalie
    Dowlati, Afshin
    Fasolo, Angelica
    Moreno, Victor
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [50] A first-in-human phase 1 study of GC1118, a novel monoclonal antibody inhibiting epidermal growth factor receptor (EGFR), in patients with advanced solid tumors.
    Lee, Keun Wook
    Oh, Do-Youn
    Han, Sae-Won
    Kim, Jin Won
    Shin, Jung-Won
    Jo, Seong-Jin
    Kim, Na Hyung
    Woo, Ahmi
    Won, Jonghwa
    Hahn, Seokyung
    Lee, Howard
    Kim, Woo Ho
    Bang, Yung-Jue
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345